Zobrazeno 11 - 20
of 4 625
pro vyhledávání: ''
Autor:
Thierry Huby, Wilfried Le Goff
Publikováno v:
Current Opinion in Lipidology. 33:167-174
Scavenger receptor class B type 1 (SR-B1) promotes atheroprotection through its role in HDL metabolism and reverse cholesterol transport in the liver. However, evidence indicates that SR-B1 may impact atherosclerosis through nonhepatic mechanisms.Rec
Publikováno v:
Journal of Cardiovascular Pharmacology. 79:335-341
This study aimed to investigate the role of ginsenoside Rh1 in regulating the proliferation, apoptosis, and oxidative stress in oxidized low-density lipoprotein (ox-LDL)-treated human vascular endothelial cells (VECs) and the underlying mechanisms. V
Publikováno v:
Current Opinion in Lipidology. 33:103-111
PURPOSE OF REVIEW: Transmembrane glycoprotein cluster of differentiation 36 (CD36) is a scavenger receptor class B protein (SR-B2) that serves various functions in lipid metabolism and signaling, in particular facilitating the cellular uptake of long
Autor:
William E. Louch, Geir Christensen, Pimthanya Wanichawan, Hilde Jarstadmarken, Enno Klussmann, Marie C. Moutty, Ivar Sjaastad, Viacheslav O. Nikolaev, Cathrine R. Carlson, Per Kristian Lunde, Laetitia Pereira, Anna Bergan-Dahl, Ole M. Sejersted, Jan Magnus Aronsen, Marianne Lunde, Terje R Selnes Kolstad, Susanne Hille, Donald M. Bers, Bjørn Dalhus, Hariharan Subramanian, Oliver Müller, Xin Shen
Publikováno v:
Circulation research, vol 130, iss 1
Background: The sarcoplasmic reticulum (SR) Ca 2+ -ATPase 2 (SERCA2) mediates Ca 2+ reuptake into SR and thereby promotes cardiomyocyte relaxation, whereas the ryanodine receptor (RYR) mediates Ca 2+ release from SR and triggers contraction. Ca 2+ /C
Autor:
Shenghua Zhou, Yuting Cui, Hao Yin, Zhihan Tang, Yu Gui, Shi Tai, Darrell D. Belke, Binjie Yan, Xi-Long Zheng, Yanan Guo, Juan Peng
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 42:67-86
Objective: PCSK9 (proprotein convertase subtilisin/kexin type 9) plays a critical role in cholesterol metabolism via the PCSK9–LDLR (low-density lipoprotein receptor) axis in the liver; however, evidence indicates that PCSK9 directly contributes to
Autor:
Yulin He, Tingyu Lan, Thekla Kemper, Yongfang Jiang, Mengji Lu, Xueyu Wang, Yong Lin, Jia Li, Bin Jiang, Zhongji Meng, Zhiqiang Wei, Bin Cheng
Publikováno v:
Hepatology. 75:438-454
Background & aims Hepatitis B virus (HBV) infection has been reported to trigger endoplasmic reticulum (ER) stress and initiate autophagy. However, how ER stress and autophagy influence HBV production remains elusive. Here, we studied the effect of t
Autor:
Keith P. Gates, P. Duc Si Dong, Jonathan Matalonga, Jiaye He, Chong Chen, Lindsey Barske, Jan Huisken, Dan Cao, Yi Yang, Chengjian Zhao, Alyssa Graves, Xiangyu Pan, Joseph J. Lancman
Publikováno v:
Hepatology
Alagille Syndrome (ALGS) is a congenital disorder caused by mutations in the Notch ligand gene JAGGED1, leading to neonatal loss of intrahepatic duct (IHD) cells and cholestasis. Cholestasis can resolve in certain patients with ALGS, suggesting regen
Autor:
Yiming Jiang, Frank J. Gonzalez, Hua Li, Ruimin Wang, Shicheng Fan, Xiao Yang, Aijuan Qu, Huichang Bi, Jianing Tian, Min Huang, Yue Gao, Shuguang Zhu, Xinpeng Yao, Tomoki Yagai, Guomin Xie
Publikováno v:
Hepatology
BACKGROUND AND AIMS: Peroxisome proliferator–activated receptor α (PPARα, NR1C1) is a ligand-activated nuclear receptor involved in the regulation of lipid catabolism and energy homeostasis. PPARα activation induces hepatomegaly and plays an imp
Publikováno v:
Curr Opin Lipidol
PURPOSE OF REVIEW: To highlight recent developments in studying mechanisms by which the apolipoprotein E4 (APOE4) allele affects the metabolism of brain lipids and predisposes the brain to inflammation and Alzheimer’s disease (AD) dementia. RECENT
Autor:
Lan Bai, Wen-Jie Zhao, Tengfei Ma, Manli Hu, Fengjiao Hu, Chongshu Jian, Han Tian, Xu Cheng, Jiajun Fu, Yanfang Zhang, Juan Yang, Zhi-Gang She, Yan-Xiao Ji, Junjie Zhou, Xiao-Jing Zhang, Peng Zhang, Yan Zhang, Jingwei Jiang, Hongliang Li
Publikováno v:
Hepatology. 75:403-418
Background & aims Although the prevalence of nonalcoholic fatty liver disease (NAFLD) has risen dramatically to 25% of the adult population worldwide, there are as yet no approved pharmacological interventions for the disease due to uncertainty about